GlassScriptPhysician profile
David Mclaren
NPI 1245207109
$1,391.09
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,205 · 2020: $159 · 2021: $26.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $297.87 | 2019-2021 | |
| Genzyme Corporation | $242.48 | 2019 | |
| Ucb, INC. | $142.70 | 2019 | |
| Amneal Pharmaceuticals LLC | $87.63 | 2019 | |
| Grifols USA, LLC | $84.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $78.71 | 2019 | |
| Emd Serono, INC. | $71.66 | 2019 | |
| Mallinckrodt Enterprises LLC | $67.65 | 2019 | |
| Avanir Pharmaceuticals, INC. | $46.71 | 2019 | |
| Amgen INC. | $37.45 | 2019 | |
| Adamas Pharmaceuticals, INC. | $37.20 | 2019 | |
| Genentech USA, INC. | $30.88 | 2019 | |
| Eisai INC. | $24.91 | 2019 | |
| Abbvie INC. | $23.47 | 2019 | |
| Acorda Therapeutics, INC | $22.93 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.85 | 2019 | |
| Medtronic USA, INC. | $18.19 | 2020 | |
| Neurocrine Biosciences, INC. | $15.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.44 | 2019 | |
| Philips North America LLC | $14.34 | 2019 | |
| Lundbeck LLC | $11.73 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mclaren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.